Opendata, web and dolomites

4-IN THE LUNG RUN SIGNED

4-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 4-IN THE LUNG RUN project word cloud

Explore the words cloud of the 4-IN THE LUNG RUN project. It provides you a very rough idea of what is the project "4-IN THE LUNG RUN" about.

morbidity    unnecessary    savings    trial    cancer    million    amongst    deaths    strategy    baseline    tested    prevent    usa    participation    cessation    25    discuss    steer    nlst    negative    score    benefits    markers    interact    intensive    interim    devastating    screening    achievable    potentially    copd    thoracic    lung    innovation    integrate    intervals    reducing    natural    thousands    practices    with    run    healthcare    rates    45    co    base    smoking    imaging    regimens    slow    relatively    strategies    model    effectiveness    personalised    nelson    history    85    health    individuals    positive    risk    outcomes    international    harm    referral    form    randomised    optimal    dutch    services    limited    24    ct    settings    unknown    belgian    guidelines    mortality    interval    safe    euros    stakeholders    retain    hard    innovative    ten    annually    saving    quality    screens    heart    conclusive    billion    recruit    huge    regarding    biomarkers    calcium    338    easily   

Project "4-IN THE LUNG RUN" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 7˙999˙948 €
 EC max contribution 7˙999˙948 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 1˙926˙250.00
2    INSTITUTE FOR DIAGNOSTIC ACCURACY RESEARCH BV NL (GRONINGEN) participant 1˙901˙500.00
3    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI IT (Milan) participant 1˙398˙500.00
4    DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG DE (HEIDELBERG) participant 677˙443.00
5    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 591˙240.00
6    INSTITUT CATALA D'ONCOLOGIA ES (L'HOSPITALET DEL LLOBREGAT) participant 526˙575.00
7    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 425˙750.00
8    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 368˙470.00
9    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 184˙220.00

Map

 Project objective

With 338,000 EU-deaths annually, lung cancer is a devastating problem. CT screening has the potential to prevent ten-thousands of lung cancer deaths annually. The positive results of the Dutch-Belgian screening trial (NELSON), with relatively low referral rates, and the NLST in the USA provided conclusive evidence. However, implementation is likely to be limited, slow and of variable quality throughout Europe, and current guidelines could easily require up to 25 million CT screens annually. The most optimal strategy in risk-based lung-thoracic screening is still unknown regarding the optimal and most cost-effective (e.g., targeted) strategy 1) to recruit, 2) to integrate smoking cessation and co-morbidity-reducing services, and 3) to determine the (risk-based) screening interval. Personalised regimens based on the baseline CT result can potentially retain 85% of the mortality reduction achievable through screening at 45% less screens, thus potentially saving much unnecessary harm associated with screening, and 0.5-1 billion Euros per year. The heart of 4-IN-THE-LUNG-RUN is a randomised controlled trial amongst 24,000 individuals evaluating whether it is safe to have risk-based less intensive screening intervals after a negative baseline CT. Various methods to improve participation of hard-to-reach individuals will be assessed in five different healthcare settings. Innovative co-morbidity reducing strategies will be tested including other markers on CT imaging, as Calcium Score and COPD. Cost impact and cost-effectiveness analyses using a natural history model will steer implementation. The experienced consortium will strongly interact with key stakeholders, and discuss interim results with key other international initiatives on CT screening, biomarkers, and smoking cessation practices. This proposal will form the evidence base for risk-based lung cancer screening with huge benefits for the EU, on health outcomes, cost savings, and innovation in the long run.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "4-IN THE LUNG RUN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "4-IN THE LUNG RUN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

HEAP (2020)

Human Exposome Assessment Platform

Read More  

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EXIMIOUS (2020)

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

Read More